OBJECTIVE: The purpose of this study was to determine whether gestagen treatment enhances the effects of β2-agonists in hormone-induced preterm delivery in pregnant rats in vivo.

STUDY DESIGN: Preterm birth was induced with a combination of mifepristone and prostaglandin E2 on day 19 of pregnancy. The animals were treated with salmeterol or gestagens (progesterone or 17α-hydroxyprogesterone) or their combination. The treatments were launched on different days (15-18) of pregnancy. The efficacy of treatment was determined in terms of the delivery time counted from the mifepristone injection.

RESULTS: Salmeterol treatment delayed premature labor by 2.4 hours, whereas the delay because of the gestagen-salmeterol combinations was more than 5 hours. Progesterone had no effect on the delivery time.

CONCLUSION: Parallel treatment with salmeterol and gestagens can be more than twice as effective as salmeterol therapy alone. These results open up a possibility for human trials of combined β2-agonist-gestagen therapy in threatening preterm delivery.

Key words: beta-mimetics, gestagens, preterm birth, rat, tocolysis

Various medications have been used in tocolytic therapy, but none have been established as effective treatment of preterm labor. Supplemental treatment with progesterone (P) has been studied to prevent preterm labor and birth1–4 and as an adjunct to treat acute preterm labor.5 It has been shown to reduce the risk of recurrent preterm birth when used prophylactically but has not been thoroughly investigated as an adjunct to tocolytic drugs. Erny et al6 found that oral P reduced uterine activity, compared with placebo, in a randomized comparison in 57 women admitted with risk of preterm labor. Noblot et al5 found that the addition of micronized P to β-mimetic treatment reduced uterine activity more quickly than β-mimetic treatment alone, but there was no effect on the prolongation of pregnancy.

It is known that P increases β2-adrenergic receptor (AR) expression during pregnancy,7 and P can alter the effects of β2-AR agonists on the pregnant myometrium.8 Gáspár et al9 demonstrated that in vivo P treatment can favorably affect the level of the β2-ARs and also enhance the uterus-relaxing effect of terbutaline in vitro. Chanrachakul et al10 found that in vitro P increased the uterus-relaxing effect of ritodrine by reducing 50% of the maximal response, amplitude, and frequency of the myometrial contractions in the isolated human pregnant myometrium.

The efficacy of the gestagen-β2-agonist combination has not been adequately investigated in vivo. In the present study, we sought an answer as to whether gestagen treatment increases the effects of β2-mimetics in hormone-induced preterm delivery in rats in vivo.

MATING OF THE ANIMALS

Mature female (180-200 g) and male (240-260 g) Sprague-Dawley rats were mated in a special mating cage. Vaginal smears were taken from the female rats and a sperm search was performed under a microscope at a magnification of ×1200. If the smear proved positive, the female rats were separated and regarded as first-day pregnant animals.

INDUCTION OF PREMATURE LABOR

Preterm labor was induced according to Rechberger et al.11 Briefly, the animals were treated with mifepristone (3 mg per 0.1 mL) and prostaglandin E2 (PGE2; 0.5 mg/animal) on day 19 of pregnancy,
which may approximately correlate to the gestation weeks 34-35 if we consider that the duration of pregnancy is 22 and 280 days in rat and human, respectively. Mifepristone was suspended in olive oil and given as a subcutaneous injection at 9:00 A.M. At 4:00 P.M, PGE2 was applied intravaginally. The delivery time of the first fetus was noted as the duration in hours from the time of mifepristone administration.

Treatments of the animals
Salmeterol xinafoate (Sigma Aldrich, Budapest, Hungary) was dissolved in a 1:1 methanol-water mixture. Alzet osmotic pumps (model 2ml; DURECT Corp, Cupertino, CA) loaded with salmeterol xinafoate solution or the vehicle was inserted subcutaneously into the back skin of rats on days 15-18 of pregnancy (which may correlate to gestation weeks 27-35 in humans) under isoflurane anesthesia (Burton's narcotic apparatus). The dose of salmeterol was 130 μg/day per animal. Pefloxacin was used in dose of 8 mg per 0.1 mL/animal to prevent subsequent infections.

P (Sigma Aldrich) or 17α-hydroxyprogesterone caproate (17P; donated by Richter Gedeon NyRt, Budapest, Hungary) was suspended in olive oil and was injected subcutaneously in a dose of 0.5 mg per 0.1 mL/day from days of pump insertions to day 20 of pregnancy. The time schedule of the animal treatments is shown on Figure 1.

Experimental design
Group A was the control group, and group B was treated with P, group C with salmeterol, group D with the combination of salmeterol and P, and group E with the combination of salmeterol and 17P. Eight rats were in each group. All the animals were operated on for osmotic minipump insertion and were treated with subcutaneous injections. The osmotic minipumps contained salmeterol or vehicle, and the subcutaneous injection contained gestagens or the vehicle.

The time schedule of the treatments and the initiation of hormone-induced preterm birth in pregnant rats treated from day 15. A, Time schedule from conception to initiation of preterm birth. The salmeterol/gestagen treatments were started on day 15 in this case. When the salmeterol-gestagen treatments were initiated later in pregnancy (on day 16, 17, or 18), the days of conception and initiation of induction were the same, implicitly. B, Time schedule from the first treatment with salmeterol-gestagen to the preterm birth. When the salmeterol-gestagen treatments were initiated later in pregnancy (day 16, 17, or 18), the animals did not receive any treatments on the earlier days, implicitly. 17P, 17α-hydroxyprogesterone caprate; M, mifepristone; P, progesterone; PB, preterm birth; PG, prostaglandin E2; S, salmeterol.

**FIGURE 1**
Time schedule of treatments and initiation of hormone-induced preterm birth

<table>
<thead>
<tr>
<th>A</th>
<th>Conception</th>
<th>Initiation of Treatments</th>
<th>Initiation of Induction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Day 15</td>
<td>Day 19</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Group A: -

Group B: P

Group C: S

Group D: P

Group E: 17P

<table>
<thead>
<tr>
<th>B</th>
<th>Initiation of PB</th>
<th>PB</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day 15</td>
<td>Day 16</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Group A: -

Group B: P

Group C: S

Group D: P

Group E: 17P

in delaying the hormone-induced preterm delivery. In contrast, in group C (salmeterol), the treatment was effective; premature birth was delayed by 2.4 hours. The group D (salmeterol–P combination) delayed labor by 5.2 hours (Figure 2).

The results were similar when the treatments started on days 16-18 of pregnancy (Figures 3-5). In each case, group D and group E (combined therapy) was more effective than group B and C (simple treatment). The difference in efficacy between groups C and D was most expressed for the treatment started on day 15 (Figure 2).

In group E, the preterm birth–delaying effect of salmeterol-17P treatment was very similar to that of the salmeterol–P combination. The difference between the 2 combinations was not significant (Figure 2).

**COMMENT**

Chanrachakul et al.10 investigated the effects of in vitro P and ritodrine on oxytocin-induced human myometrial contractility. They reported that P significantly enhances the relaxant effect of the β2-mimetic by reducing both the amplitude and the frequency of the contractions. These previous results led us to test the efficacy of salmeterol-gestagens (P and 17P) treatment in hormone-induced preterm delivery in rat in vivo. We used the same in vivo P dose that had proved effective in increasing the effect of the β2-agonist in our earlier study.9 An in vivo dose for the tocolytic effect of salmeterol was not available for the rat; we therefore chose the dose used by Moore et al.12 This dose was able to induce muscular growth in the rat, indicating the systemic effect of the drug.12

Interestingly, although delivery did result from the P antagonist mifepristone in combination with PGE2, the gestagen treatment did not prevent the hormone-induced premature labor. Salmeterol treatment was effective in delaying preterm labor, and this effect was doubled by its combination with gestagens, independently of the first day of treatment: even 1 day of gestagen treatment before the administration of mifepristone and PGE2 potentiated the effect of salmeterol. This result means that the enhanced synergistic effect of gestagens can develop rapidly. The improved efficacy of the combination can very probably be explained by the gestagen-induced increases in the myometrial β2-AR density and the amount of activated G proteins coupled to β-ARs, as found earlier.9

It should be emphasized that there are some limitations of our study. We at-
The effects of P (0.5 mg per 0.1 mL), salmeterol (130 μg/day), and combined P-salmeterol treatments on hormone-induced preterm delivery in the rat (n = 8 for each group). The treatments were started on gestation day 17. A, control group; B, P-treated animals; C, salmeterol-treated animals; D, salmeterol–P combination-treated animals. The bar graphs show means ± SEM. The effects were compared with the results on the control group. ns, not significant. Asterisk indicates P < .05; double asterisks indicate P < .01; triple asterisks indicate P < .001. The difference in efficacy between the treatments reflected in groups C and D was significant (P < .05). B, Time to delivery from the initiation of preterm birth (mifepristone treatment). The longest delay was caused by the combination of salmeterol-P (4.3 hours).


A comparison of the LPS- and the hormone-induced models clearly reveals that the process of LPS-induced delivery is slower, and therefore, there may be a greater chance of reaching a longer prolongation of the whole process than in the case of hormone-induced preterm birth, in which the process is drastic and has been completed within 24 hours. Accordingly, the more than 5-hour delay in the hormone-induced model should be regarded as a significant and promising effect of the combinations of salmeterol and the gestagen compounds.

Another weakness of this study is that the experiments do not provide any data about the prompt effect of the drugs in the onset of the hormone-induced preterm birth, but the investigation of a prompt effect is almost impossible in rats. The first visual sign of the onset of labor is vaginal bleeding. From this time on, we have a maximum of only 10-15 minutes (frequently much less) until the delivery of the first fetus. This short period is surely not enough for the absorption of drugs administered extravasally, whereas intravenous administration is not appropriate for the gestagens. Additionally, the osmotic minipump is not really suitable for fast treatment. Nevertheless, in spite of all these weaknesses, our study is the first in which an attempt is made to delay the antigenestagin–prostaglandin-induced preterm birth in vivo.

The fact that the gestagens potentiate the uterus-relaxing effect of β2-agonists may yield a possibility for avoiding or diminishing the overuse of β2-agonists and the pregnancy-induced desensitization of β2-ARs.9,15,16

We conclude that a putative therapeutic combination of a β2-AR agonist and a gestagen compound may enhance the efficacy of human tocolytic therapy. Although it is very difficult to transpose such a result from an animal study into human practice, we presume that the delay of more than 5 hours caused by the salmeterol-gestagen in rat preterm delivery is very promising for human trials. If we consider that both β2-mimetics and gestagens are well known with regard to their pharmacokinetics and toxicity, the expected therapeutic risk of their combination is relatively low. In view of all the preclinical results and earlier experience with the drugs, we think that
there is sufficient evidence indicative of the potentiation of the $\beta_2$-mimetic effect by gestagens in pregnant uterine relaxation. The time may have come to begin trials to clarify the effects of such a combination in human preterm birth.

ACKNOWLEDGMENT

Special thanks go to Anna Klukovits, PhD, and Renáta Minorics, PhD, for their contribution to the experimental work.

REFERENCES